February 2007

A Feb. 23 column by Adam Feuerstein titled Merck-Gilead Drug Duel Is Heating Up was incomplete as originally published. Due to an editing error, four paragraphs were inadvertently omitted from the column. The missing material is as follows:

To that end, Merck and Gilead have developed drugs that fight HIV by inhibiting integrase. Specifically, integrase is the enzyme responsible for allowing viral DNA to enter the nucleus of the host cell and integrate into the host cell genome. Clinical data presented so far by both companies have excited HIV researchers because integrase inhibitors appear to be very effective in fighting the virus with fewer side effects than current HIV medicines.

Merck's drug goes by the name MK0518. At the CROI meeting, Merck will present for the first time clinical data from two phase III studies testing MK0158 in combination with other HIV drugs in treatment-experienced HIV patients. Said another way, these are patients in whom the virus has developed resistance to certain current HIV drugs.

Merck has already announced plans to seek approval of MK0158 with the Food and Drug Administration in the middle of the year. MK0518 could be approved and on the market by early next year, if Merck proceeds on plan.

Gilead's integrase inhibitor is called GS 9137. At CROI, data will be presented from a phase IIb study of GS 9137, also in treatment-experienced HIV patients. Gilead has already stated that it will start phase III studies of GS 9137 in mid-2007. If so, data should be available in mid-2008 and the drug could be approved in early 2009.

TheStreet.com regrets the error. (Corrected Feb. 23)

---

Because of a typographical error, a Feb. 19 column, Holiday Portfolio: Carrizo Ahead in the Polls, reported that Carrizo (CRZO) was set to test an exploration well that could lead to the discovery of a natural gas field with more than 500 million cubic feet of natural gas reserves. The field could actually have more than 500 billion cubic feet of natural gas reserves. TheStreet.com regrets the error. (Corrected Feb. 21)

---

The Feb. 15 Mad Money Recap containted the wrong future stock symbol for Clearwire, a wireless broadband company whose IPO on the Nasdaq is scheduled for next week. The correct symbol is CLWR, not CWTR, which is that of retailer Coldwater Creek. TheStreet.com regrets the error. (Corrected Feb. 16)

---

A Feb. 7 story, Forex Funds for Bulls and Bears, incorrectly stated that two mutual funds, the Rising U.S. Dollar ProFund (RDPIX) and the Falling U.S. Dollar ProFund (FDPIX), use leverage to amplify the rise or fall of the U.S. Dollar Index. Neither fund employs leverage; the Rising U.S. Dollar ProFund seeks to match the daily performance of the index, while the Falling U.S. Dollar ProFund seeks to match the inverse performance of the index. TheStreet.com regrets the error. (Corrected Feb. 16)

---

A Feb. 15 column by David Merkel titled Risk Some Capital on This Insurer, contained an error. The column stated that it's the wrong point in the interest rate cycle to purchase Employers Holdings; it should have indicated that it's the wrong point in the pricing cycle to own the stock, because premium rates are declining. TheStreet.com regrets the error. (Corrected Feb. 15)

---

A Feb. 13 story, U.S. Seeks More China Flights, incorrectly stated that United Airlines (UAUA) has been granted the authority to begin flying a Washington-Shanghai route next month. The authorized route is Washington-Beijing. TheStreet.com regrets the error. (Corrected Feb. 13)

---

A Feb. 12 column titled Don't Like the Tape, Love the Prospects contained an error. The column stated incorrectly that BKX is the biotech index; it is the banks index. The BTK is the biotech index. TheStreet.com regrets the error. (Corrected Feb. 12)

---

A Feb. 12 article, Morgan Stanley's Real Estate Push, misstated the value of domestic real estate acquisitions by private equity investors last year. It was $62.4 billion, according to Dealogic -- not $177.6 billion. TheStreet.com regrets the error. (Corrected Feb. 12)

---

A Feb. 9 story, Former TWA Attendants Press On, misstated the starting annual salary for flight attendants at American Airlines (AMR) as $23,000. It's $16,000. TheStreet.com regrets the error. (Corrected Feb. 9)

---

A Feb. 8 article, Subpar Subprime a Growing Problem, incorrectly stated that Fieldstone Investment Corp. (FICC) had filed for bankruptcy. The company has not filed for bankruptcy. TheStreet.com regrets the error. (Corrected Feb. 9)

---

A Feb. 8 story, Gateway Swings to Profit, initially reported that the company's fourth-quarter profit fell from the same quarter a year earlier. In fact, the company had reported a loss in the year-ago quarter. TheStreet.com regrets the error. (Corrected Feb. 8)

---

A Feb. 6 article, Vertex Nears Hit or Miss, misstated the timeline for an FDA filing of telaprevir as likely to occur in mid-2008. Vertex's (VRTX) guidance is for an FDA filing in late 2008. TheStreet.com regrets the error. (Corrected Feb. 8)

---

A Jan. 24 article, TheStreet.com TV Recap: Tech Signs, contained an error. It indicated that Jim Cramer said AT&T management made clear on the company's recent earnings conference call that AT&T would use the iPhone to win customers from Verizon by giving away service for a year and a half to those customers who buy the iPhone. Cramer actually said that it was clear to him from the call that this was a strategy AT&T could pursue. TheStreet.com regrets the error. (Corrected Feb. 2)

---

A Feb. 5 column, Slackers in the Speculative Sector, mistakenly stated that the S&P 100, the S&P Mid-Cap 400 and the Russell 2000 all have broken to the upside and above their respective spring 2005 highs. However, those indices actually broke above their respective spring 2006 highs. TheStreet.com regrets the error. (Corrected Feb. 5)